Europe’s drugs regulator is reviewing possible links between blood clots and Johnson & Johnson’s coronavirus vaccine. It comes after four serious cases of rare clots with low platelets were reported after the COVID-19 jab, one of which was fatal, according to the European Medicines Agency (EMA).
The Johnson & Johnson (also known as Janssen) vaccine, which has proved 67% effective in preventing coronavirus and completely effective at preventing hospital admissions and death from the virus during trials, is currently only used in the USA, under an emergency use authorisation.
